Health Loom
← All answered questions

Is an HbA1c of 6.8 Good Enough?

Inside this episode

The video’s narration, chapter by chapter, with stills from the video and every source at the end.

The short version

Welcome to Health Loom. Here's the short version. 6.8 is under 7, a common general goal for adults with type 2 diabetes. But groups differ, and your own goal is one you and your clinician set together. And one result can't show a trend.

What the number measures

HbA1c, or A1c, is the share of hemoglobin, the oxygen carrier in red blood cells, that has sugar stuck to it. More sugar in the blood over time means a higher share. Red cells last a few months, so A1c reflects roughly the past two to three months, weighted toward recent weeks.

From the video: WHAT A1C MEASURES, red blood cell with hemoglobin (drawing), sugar stuck to some hemoglobin, more sugar over time → higher %, ~3 months ago, test day, Roughly the past 2–3 months, recent weeks count most, Illustration, not real data, bar height = how much each stretch counts, NGSP (“a weighted average”)
What A1C measures

Targets, and who sets yours

There's no single number every group agrees on. Diabetes Canada says 7 or below for most; a U.S. health institute, below 7 for many. The American College of Physicians suggests 7 to 8 for most. Korea's diabetes association, below 6.5. And all say to personalize it.

From the video: GENERAL GOALS DIFFER, Diabetes Canada · US NIDDK, 7 or below “in most” · below 7 “for many”, 7 or below, ←, American College of Physicians, 7 to 8 “in most” · 2018, 7 to 8, Korean Diabetes Association, below 6.5 · 2025, below 6.5, ←, 6, 6.5
General goals differ. Imran et al. (Diabetes Canada), Can J Diabetes 2018; Qaseem et al. (ACP), Ann Intern Med 2018 +2 more.

So how do clinicians personalize it? Some guidelines suggest tighter goals for some people early in diabetes, if reachable without low blood sugar. Looser goals may suit people with severe lows, limited life expectancy, serious illnesses or long-standing, hard-to-control diabetes. Preferences, treatment burden, your medicines and other conditions count too.

Why not aim lower? In the UKPDS trial, tighter control from diagnosis paid off slowly, with slightly fewer heart attacks and deaths. But in the ACCORD trial, aiming below 6 in people starting at 7.5 or higher, with about ten years of diabetes and high heart risk, was stopped early: over three and a half years, 5 in 100 died versus 4, cause unclear, and serious lows tripled.

From the video: WHY NOT AIM LOWER?, UKPDS (UK, from 1977), newly diagnosed; drugs vs diet:, reached ~7 vs ~8, trial, decades later, Slightly fewer heart attacks, and deaths, over decades:, about 3 fewer deaths per 100, ACCORD (US, Canada, from 2001), starting A1c 7.5–11,, ~10 years of diabetes, high heart risk, Aimed b
Why not aim lower? UKPDS Group, Lancet 1998; ACCORD Group, NEJM 2008 +3 more. Dots: our arithmetic. (drawings)

Medicines matter too. On its own, metformin rarely causes low blood sugar, its label says, though it can happen if you don't eat enough, drink alcohol, or take other diabetes medicines. Insulin and diabetes pills called sulfonylureas carry more risk. Some guidelines allow lower goals only if reached safely, a call made with your clinician.

What one result can tell you

One result can't show a trend, and tests vary. A U.S. government health page happens to use 6.8 as its example: a repeat test on the same sample could read from about 6.4 to 7.2, a range it says used to be wider. And conditions like iron-deficiency anemia, kidney failure or recent blood loss can skew A1c.

From the video: ONE RESULT, One result: a level, not a trend, Screenshot: NIDDK, The A1C Test & Diabetes (last reviewed Apr 2018; cropped), 6, 6.4, 6.8, 7.2, 7.6, NIDDK’s example: same sample, retested, Range used to be wider, Can make A1c read too high or too low:, iron-deficiency anemia, · kidney failure, · recent bl
ONE result. Screenshot: NIDDK, The A1C Test & Diabetes (last reviewed Apr 2018; cropped)

And the new routine? Our listener started gym visits and evening walks three to six months ago. In trials, where people started near 7.7 on average, structured exercise, including walking programs, lowered A1c by about half a point. That's an average, not a prediction. By our arithmetic, a July test came anywhere from just before the routine to a few months in, so alone it can't show what exercise did; a later result will say more.

Keeping it up is the hard part. In the Look AHEAD weight-loss trial, fewer than 1 in 3 people met its strict activity goal after a year. Ongoing counseling, supervised sessions and step goals have modest, mixed support.

From the video: KEEPING IT UP, 29 in 100, reached 175 min/week, counted by a monitor in 10-min bouts, at 1 year, Look AHEAD lifestyle (weight-loss) group, Modest, mixed support:, ongoing counseling (one Italian trial), · supervised sessions, · step goals, Unick et al., Med Sci Sports Exerc 2016; MacDonald et al., Diabe
Keeping it up. Unick et al., Med Sci Sports Exerc 2016; MacDonald et al., Diabetes Metab Res Rev 2021 +6 more. Dots: 29 of 100.

So 6.8 is under 7, a common general goal, but your goal is personal. Questions for your clinician: What goal fits me, and why? When should we recheck, and what change would matter? Could anything skew my result? And does my treatment carry any risk of low blood sugar, including with exercise?

Sources

31 sources cited in the video, in the order they come up.

Intro

  1. Qaseem 2018, Ann Intern Med: American College of Physicians guidance (7 to 8 "in most"; goals personalized "on the basis of a discussion"; funding and authors' declarations unread, no open full text)
  2. Kang 2025, Diabetes Metab J: Korean Diabetes Association guideline (below 6.5; funded by the KDA; authors include journal editors, declared)
  3. Imran 2018, Can J Diabetes: Diabetes Canada, Targets for Glycemic Control (7 or below "in most"; 2 of 4 authors report fees or grants from diabetes-drug makers): ; chapter page [link 2]
  4. NIDDK, The A1C Test & Diabetes (targets differ from person to person; last reviewed Apr 2018)
  5. NIDDK, Diabetes, Heart Disease, & Stroke (below 7 "for many"; last reviewed Apr 2021)
  6. Short-version footer "+2 more": "a common general goal" (under 7) also rests on Araki 2020 (Japan Diabetes Society, below) and Cheung 2009, Med J Aust: Australian Diabetes Society, a 2009 position statement (7.0 or below "for most"; old, not current Australian guidance)

What the number measures

  1. NGSP, HbA1c and eAG ("a weighted average" of the past few months; NGSP is supported in part by NIDDK)

Targets, and who sets yours

  1. UKPDS Group 1998, Lancet (UKPDS 33: newly diagnosed, drugs vs diet, reached about 7 vs about 8; funders not read)
  2. Holman 2008, NEJM (UKPDS 80: 10-year post-trial follow-up, observational; BHF, MRC, NIHR and Wellcome grants)
  3. Adler 2024, Lancet (UKPDS 91: about 3 fewer deaths per 100 over decades, compared with diet first; University of Oxford funding)
  4. ACCORD Study Group 2008, NEJM (abstract read; aiming below 6 was stopped early; 257 vs 203 deaths, about 5 vs 4 in 100 by our arithmetic; NIH and CDC funding, companies supplied drugs and equipment)
  5. ACCORD's "about ten years of diabetes" comes from Hemmingsen 2011, BMJ, Table 3 (mean or median; some authors had Novo Nordisk ties) and Boussageon 2011, BMJ, Table 1 (no specific funding) , not from the ACCORD abstract [link 2]
  6. Bonds 2010, BMJ (ACCORD: starting A1c 7.5 to 11; serious lows needing medical help 10.3% vs 3.4%; cause of the extra deaths unclear; authors include a full-time Lilly employee and others with industry ties; used here only for event counts from an NIH-funded trial)
  7. Paper shot, shown on screen: Metformin label (Zydus), Patient Information, DailyMed, updated 15 Jul 2026 (excerpts). Source: National Library of Medicine
  8. NIDDK, Low Blood Glucose (Hypoglycemia) (insulin and sulfonylurea pills; last reviewed Jul 2021)
  9. Araki 2020, J Diabetes Investig: Japan Diabetes Society guideline 2019 (a tighter goal only "without developing hypoglycemia"; many authors report industry fees or grants)

What ONE result can tell you

  1. Screenshot, shown on screen: NIDDK, The A1C Test & Diabetes, "How precise is the A1C test?" (last reviewed Apr 2018; cropped). Shown for what it said: its own 6.8 example could read 6.4 to 7.2 on a repeat test of the same sample, a range it says used to be wider
  2. NGSP, Factors that Interfere with HbA1c Test Results (updated Jun 2026; examples, not a full list)
  3. Paper shot, shown on screen: Qiu 2014, PLOS ONE (walking trials; title block and one abstract sentence; CC BY; −0.50 points pooled from 16 trials, 724 people; results varied widely; no competing interests): ; PubMed [link 2]
  4. Michielsen 2025, Cardiovasc Diabetol (100 trials; average start 7.7%, a mean of trial means, range 5.9 to 10.5; possible publication bias; FWO-funded, no competing interests)
  5. Umpierre 2011, JAMA (structured exercise programs; authors' declarations unread)
  6. Boulé 2001, JAMA (an older review, a similar average drop; authors' declarations unread)
  7. Unick 2016, Med Sci Sports Exerc (Look AHEAD: 29 in 100 in the lifestyle group reached 175 min a week, counted by a monitor in 10-min bouts, at 1 year; NIDDK-funded)
  8. Ryan 2003, Control Clin Trials (Look AHEAD design paper: a weight-loss trial; abstract read)
  9. Balducci 2019, JAMA, IDES_2: ongoing counseling kept 300 inactive adults a little more active over 3 years (one Italian trial; 3 clinics in Rome; conflicts of interest unread)
  10. MacDonald 2021, Diabetes Metab Res Rev (sticking with programs: median 58%, higher with supervised training; one study at low risk of bias; NIH and TrygFonden funding)
  11. Bullard 2019, BMC Public Health (home programs did about as well as clinic ones)
  12. Qiu 2014, BMC Med (step counters: more steps, mostly with a goal; A1c didn't change)
  13. Avery 2015, Diabet Med (supervision not linked to more activity; smaller effects with pedometers; MRC, NIHR and EU funding)
  14. Cradock 2017, Int J Behav Nutr Phys Act (diet-and-activity trials: the drop was largest early; Irish Research Council funding)

Before you go

  1. Questions footer "+3 more": NGSP (when to recheck, on its HbA1c and eAG page; what can skew a result, on its factors page; both above) and the studies behind "what change would matter": Ucar 2013, Clin Biochem ; Braga 2011, Clin Chim Acta (small studies of healthy adults; no number aired) [link 2]

More answered questions